All In Biotech

NDA 211039 · Bausch Lomb Ireland

Fluorescein Sodium and Benoxinate Hydrochloride

Benoxinate Hydrochloride, Fluorescein Sodium · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Mar 9, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Mar 9, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

16

4 Phase 3, 2 recruiting

FAERS reports

3

3 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 12, 2025.

Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is indicated for ophthalmic procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent. Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is a combination of fluorescein sodium, a disclosing agent and benoxinate hydrochloride, a local ester anesthetic indicated for procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic. ( 1 )

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE · BENOXINATE HYDROCHLORIDE 0.4%; FLUORESCEIN SODIUM 0.3% · SOLUTION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Benoxinate" as an intervention, any sponsor and status, largest first.

All 16 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • syncope2
  • abdominal pain upper1
  • blood glucose decreased1
  • confusional state1
  • disorientation1
  • dizziness1
  • dysarthria1
  • dyspnoea1
  • fatigue1
  • feeling hot1
  • headache1
  • heart rate increased1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20151
20191
20241

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8 on PubMed

Sponsor: Bausch Lomb Ireland

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.